89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Clinical trial NCT05563272 · TERMINATED

Trial details

NCT number: NCT05563272
Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Cervical Cancer Colorectal Cancer Esophageal Cancer Gastric Cancer Glioblastoma Multiforme Cholangiocarcinoma Hepatocellular Carcinoma Head and Neck Squamous Cell Carcinoma Nasopharyngeal Carcinoma Non Small Cell Lung Cancer Small Cell Lung Cancer Epithelial Ovarian Cancer

Start date: 2023-06-06
Primary completion: 2025-05-09
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.